Overview

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Status:
Recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are refractory to Janus Kinase (JAK)-Inhibitor treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Geron Corporation

Treatments:

Imetelstat
Motesanib diphosphate